申请人:Nishimura Toshihiro
公开号:US20060142209A1
公开(公告)日:2006-06-29
The present invention provides glucopyranosyloxypyrazole derivatives represented by the general formula:
wherein one of Q and T represents a group represented by the general formula:
while the other represents a lower alkyl group or a halo(lower alkyl) group; R
1
represents a hydrogen atom, an optionally substituted lower alkyl group, a lower alkenyl group, a cyclic lower alkyl group, etc.; R
2
represents a hydrogen atom, an optionally substituted lower alkyl group, a lower alkoxy group, a lower alkenyl group, a cyclic lower alkyl group, a cyclic lower alkoxy group, etc., which exert an excellent inhibitory activity in human SGLT2, and therefore are useful as drugs for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, pharmaceutically acceptable salts thereof or prodrugs thereof, production intermediates thereof and pharmaceutical uses thereof.
本发明提供一种由下式表示的葡萄糖吡唑衍生物:其中Q和T中的一个表示由下式表示的基团:而另一个表示较低的烷基或卤代(较低的烷基)基团;R1表示氢原子、可选地取代的较低烷基基团、较低烯基基团、环状较低烷基基团等;R2表示氢原子、可选地取代的较低烷基基团、较低烷氧基基团、较低烯基基团、环状较低烷基基团、环状较低烷氧基基团等,这些化合物在人类SGLT2中表现出优异的抑制活性,因此可用作预防或治疗与高血糖相关的疾病,如糖尿病、糖尿病并发症或肥胖症的药物,其药学上可接受的盐或前药,其生产中间体以及其制药用途。